New study treatment for idiopathic pulmonary fibrosis
Part of Lungs & breathing clinical trials.
This study tests a new medicine called AGMB-447 for people with idiopathic pulmonary fibrosis (IPF), a condition where lung tissue becomes scarred and breathing becomes harder. The goal is to see if the treatment is safe and helps improve lung function.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be 40 years or older.
- You must have been diagnosed with IPF within the last 7 years.
- Your lung function must meet certain levels: a breathing test (FVC) of at least 45% of normal, a ratio (FEV1/FVC) above 0.7 or within normal limits, and a measure of how well your lungs transfer oxygen (DLCO) of at least 25% of normal.
- You must either be on a stable dose of standard IPF treatment (like pirfenidone or nintedanib) for 8 weeks before the study, or not be on such treatment (if new to treatment or you couldn't tolerate it) and be stable for at least 4 weeks.
- You must not have other lung diseases besides IPF, and you must not have had a lung infection or flare-up of IPF in the recent months before the study.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new medicine called AK3280 to see if it can help people with idiopathic pulmonary fibrosis (a lung disease that causes scarring). It aims to slow down the worsening of lung function. If you have IPF and haven't been treated with anti-fibrotic drugs recently, you might be able to join.
This trial tests a new drug called BC006 for people with idiopathic pulmonary fibrosis (IPF), a lung condition that causes scarring. The goal is to see if it can help improve lung function. You may be eligible if you are 40 or older and have a confirmed IPF diagnosis with specific lung test results.
This trial is testing a new medication called HSK50042 to see if it can help people with idiopathic pulmonary fibrosis (IPF), a lung condition that causes scarring. If you have IPF and meet some basic health criteria, you might be able to join.
This trial tests a new drug, SB17170, for people with IPF. It aims to see if the drug can help slow down lung damage. You may be eligible if you have a confirmed diagnosis of IPF and meet certain lung function criteria.
This Phase 2 study tests whether an oral medication (INS018_055) can help people with idiopathic pulmonary fibrosis (IPF). You may be a fit if your lung function is in a certain range and your condition is stable.
This trial tests a new drug called SV001 to see if it is safe and tolerable for people with idiopathic pulmonary fibrosis (IPF). If you have IPF and meet certain health criteria, this study may help find new treatment options.
Hear when a new Idiopathic Pulmonary Fibrosis (IPF) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.